KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Research & Development: 2014-2024

Historic Research & Development for BeOne Medicines (ONC) over the last 11 years, with Dec 2024 value amounting to $2.0 billion.

  • BeOne Medicines' Research & Development rose 5.54% to $523.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 8.77%. This contributed to the annual value of $2.0 billion for FY2024, which is 9.82% up from last year.
  • Latest data reveals that BeOne Medicines reported Research & Development of $2.0 billion as of FY2024, which was up 9.82% from $1.8 billion recorded in FY2023.
  • In the past 5 years, BeOne Medicines' Research & Development ranged from a high of $2.0 billion in FY2024 and a low of $472.5 million during FY2021.
  • For the 3-year period, BeOne Medicines' Research & Development averaged around $1.8 billion, with its median value being $1.8 billion (2023).
  • Its Research & Development has fluctuated over the past 5 years, first tumbled by 63.51% in 2021, then spiked by 247.22% in 2022.
  • Over the past 5 years, BeOne Medicines' Research & Development (Yearly) stood at $1.3 billion in 2020, then slumped by 63.51% to $472.5 million in 2021, then soared by 247.22% to $1.6 billion in 2022, then climbed by 8.42% to $1.8 billion in 2023, then increased by 9.82% to $2.0 billion in 2024.